Exelixis, Inc. $EXEL Shares Bought by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. grew its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 22.2% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 100,600 shares of the biotechnology company’s stock after buying an additional 18,300 shares during the period. Hillsdale Investment Management Inc.’s holdings in Exelixis were worth $4,155,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. TriaGen Wealth Management LLC purchased a new position in Exelixis during the third quarter worth approximately $2,024,000. BridgePort Financial Solutions LLC acquired a new stake in shares of Exelixis in the 3rd quarter worth $517,000. Candriam S.C.A. raised its holdings in shares of Exelixis by 18.4% during the 3rd quarter. Candriam S.C.A. now owns 696,104 shares of the biotechnology company’s stock worth $28,749,000 after acquiring an additional 108,367 shares during the period. Allianz Asset Management GmbH boosted its position in shares of Exelixis by 153.3% during the 3rd quarter. Allianz Asset Management GmbH now owns 2,462,948 shares of the biotechnology company’s stock valued at $101,720,000 after acquiring an additional 1,490,520 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Exelixis in the second quarter valued at about $321,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. TD Cowen reaffirmed a “buy” rating on shares of Exelixis in a research note on Wednesday, November 5th. Guggenheim lowered shares of Exelixis from a “buy” rating to a “neutral” rating in a research report on Monday, November 3rd. Morgan Stanley increased their price objective on Exelixis from $48.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Monday, February 2nd. Barclays lifted their target price on Exelixis from $41.00 to $44.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 4th. Finally, HC Wainwright increased their price target on Exelixis from $52.00 to $54.00 and gave the stock a “buy” rating in a report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Exelixis presently has an average rating of “Hold” and a consensus price target of $47.11.

Insider Activity at Exelixis

In related news, EVP Patrick J. Haley sold 67,814 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $43.52, for a total transaction of $2,951,265.28. Following the sale, the executive vice president directly owned 381,908 shares of the company’s stock, valued at $16,620,636.16. This represents a 15.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Brenda Hefti sold 18,669 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $44.01, for a total transaction of $821,622.69. Following the completion of the transaction, the senior vice president directly owned 96,512 shares of the company’s stock, valued at $4,247,493.12. This represents a 16.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 285,058 shares of company stock valued at $12,460,245. 2.85% of the stock is owned by company insiders.

Exelixis Stock Down 1.2%

NASDAQ:EXEL opened at $43.63 on Monday. Exelixis, Inc. has a 52 week low of $32.38 and a 52 week high of $49.62. The stock’s fifty day moving average is $43.88 and its two-hundred day moving average is $41.25. The stock has a market capitalization of $11.33 billion, a price-to-earnings ratio of 15.75, a price-to-earnings-growth ratio of 0.98 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.20. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The firm had revenue of $598.66 million for the quarter, compared to the consensus estimate of $609.17 million. During the same quarter in the previous year, the business earned $0.55 EPS. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. On average, sell-side analysts expect that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.